Exagen Inc. Stock News

Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript

Exagen Inc. (XGN) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.58 per share a year ago.

CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 202

Exagen Inc. (XGN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that

Exagen Inc. (NASDAQ:XGN ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Conference Call Partici

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2023, a

SAN DIEGO, California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Cantor Fitzgera

Exagen Inc. (XGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.78 per share a year ago.

SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2023, before

Exagen Inc. (NASDAQ:XGN ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Kamal Adawi

Exagen Inc. (XGN) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.60 per share a year ago.

The stock price of Exagen Inc (NASDAQ: XGN) fell by 14.89% after hours in the most recent trading session. This is why.

Exagen Inc. (NASDAQ:XGN ) Q4 2022 Results Conference Call March 20, 2023 4:30 PM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President and Chief Executive Officer Kamal Ada

Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.31% and 48.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (NASDAQ:XGN ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Mark Hazeltine - Chief